[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"premature-coronary-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:premature-coronary-heart-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,62,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053702","phase-1-a-study-of-verve-102-in-patients-with-familial-hypercholesterolemia-or-premature-coronary-artery-disease-100053702",false,"NCT06164730","A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease","Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein Cholesterol","Inclusion Criteria:\n\n* Diagnosis of HeFH or premature CAD\n\nExclusion Criteria:\n\n* Homozygous familial hypercholesterolemia\n* Active or history of chronic liver disease\n* Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol","ALL","18 Years","70 Years",{"count":20,"type":21},85,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.",[27,28],"Heterozygous Familial Hypercholesterolemia","Premature Coronary Heart Disease",[30,31,32,33,34,35,36],"VERVE-102","Familial Hypercholesterolemia","Coronary Artery Disease","Dose Escalation","Gene Editing","Base Editing","heart-2","RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2024-04-30",{"date":45,"type":21},"2027-08",{"name":47,"class":48},"Verve Therapeutics, Inc.","INDUSTRY",24,{"id":51,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":25,"conditions":54,"keywords":55,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":61,"locationsCount":49},"100528742",{"count":20,"type":21},[24],[27,28],[30,31,32,33,34,35,36],"2026-06-26",{"date":58,"type":41},"2026-06-29",{"date":43,"type":41},{"date":45,"type":21},{"name":47,"class":48},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":93},"100595367","effectiveness-of-an-ai-enabled-stratified-management-system-for-premature-coronary-artery-disease-100595367","NCT07031531","Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease","Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease (SMART-CHD): A Prospective, Multicenter, Open-Label, Randomized Controlled Trial","SMART-CHD","Inclusion Criteria\n\n1. Patients with coronary heart disease aged 18-45 years;\n2. The patient or a close family member is capable of using a smartphone and mobile application (App);\n3. Willing to participate in the study and able to provide written informed consent.\n\nExclusion Criteria\n\n1. Severe cognitive impairment;\n2. Advanced-stage malignancy;\n3. Life expectancy less than 12 months;\n4. Severe multi-organ failure;\n5. Refusal to provide written informed consent.","45 Years",{"count":72,"type":21},4900,[74],"NA","The goal of this clinical trial is to learn if an AI-enabled stratified management system (SMART-CHD) can improve post-discharge outcomes in adults aged 18-45 with premature coronary artery disease. The main questions it aims to answer are:\n\n1. Does SMART-CHD reduce the combined rate of all-cause death, myocardial infarction, stroke and rehospitalization within 12 months?\n2. Does SMART-CHD achieve better control of modifiable risk factors compared with usual care?\n\nResearchers will compare SMART-CHD to standard discharge management (verbal and printed instructions on medications, follow-up timelines and lifestyle advice) to see if the AI-driven platform leads to fewer adverse events and improved risk-factor profiles.\n\nParticipants will:\n\n1. Install and use the SMART-CHD mobile app after a 10-minute structured orientation session with supervised simulations.\n2. Complete regular in-app surveys on lifestyle behaviors, laboratory\u002Fimaging results and clinical events (with OCR-powered LLM assistance).\n3. Wear paired sensors for continuous monitoring of blood pressure, heart rate and other physiologic metrics.\n4. Receive automated EHR data harvesting, AI-driven voice-call reminders, and real-time CRC support via a dedicated WeChat group.\n5. Follow personalized, guideline-based risk-factor recommendations (diet, exercise, sleep, weight, smoking, alcohol, hypertension, dyslipidemia, diabetes).",[28],[78,79,80,81,82],"Premature coronary heart disease","secondary prevention","long-term management","mobile health","artificial intelligence","2025-09-18",{"date":85,"type":41},"2025-09-23",{"date":87,"type":41},"2025-08-08",{"date":89,"type":21},"2027-07-31",{"name":91,"class":92},"China National Center for Cardiovascular Diseases","OTHER_GOV",16,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},"100593285","multi-modal-adverse-events-prediction-for-premature-coronary-heart-disease-trial-map-chd-trial-100593285","NCT07004452","Multi-modal Adverse Events Prediction for Premature Coronary Heart Disease Trial: MAP-CHD Trial","Inclusion Criteria:\n\n* Age 18-45 years;\n* Clinically confirmed CAD with ≥50% luminal stenosis in at least one major coronary artery or significant branch, verified by coronary angiography;\n* For acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) patients: clinical stability meeting discharge criteria post-treatment;\n* Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n* Heart transplant recipients;\n* Severe systemic comorbidities with life expectancy \\\u003C1 year;\n* Previous enrollment in other drug\u002Fdevice clinical trials without completing the primary endpoint observation period;\n* Inability to comply with follow-up (e.g., dementia, severe psychiatric disorders).",{"count":101,"type":21},5000,"OBSERVATIONAL","The goal of this observational cohort study is to establish a risk prediction model for adverse events in Chinese individuals under 45 years old with premature coronary artery disease. The main questions it aims to answer are:\n\n* What are the major risk factors for poor prognosis in Chinese patients with premature coronary artery disease?\n* What is the difference in the prognosis of patients with premature coronary heart disease with different phenotypes? Participants taking no mandatory intervention will be followed up for 2 year, with blood tests at 1 year and outpatient or telephone interviews at other timepoints.",[28],"2025-05-27",{"date":107,"type":41},"2025-06-04",{"date":109,"type":41},"2025-03-31",{"date":111,"type":21},"2027-07",{"name":91,"class":92},1]